This randomised, cross-over study (n=7) used precision functional mapping with high-resolution multi-echo fMRI to characterise psilocybin (25mg) versus methylphenidate effects on brain networks, revealing decreased network modularity during psilocybin exposure and reproducible network changes. Participants showed unique brain configurations and reported stronger mystical experiences with psilocybin compared to methylphenidate.
Psilocybin (PSIL) is a psychedelic drug and a promising experimental therapeutic for many psychiatric conditions. Precision functional mapping (PFM) combines densely repeated resting state fMRI sampling and individual-specific network mapping to improve signal-to-noise ratio (SNR) and effect size in brain imaging research. We present a randomized cross-over study in which PFM was used to characterize acute and persistent effects of psilocybin or methylphenidate (MTP) on brain networks. Seven healthy volunteers (mean age 34.1 years, SD = 9.8; n = 3 females, n = 6 Caucasians) underwent (1) extensive baseline imaging, (2) imaging beginning 60-90 minutes after drug exposure, and (3) longitudinal imaging for up to two weeks after drug exposure. Four individuals also participated in an open-label PSIL replication protocol over 6 months later. This dataset includes resting state (using advanced high-resolution multi-echo fMRI), task fMRI, structural, and diffusion basis spectral imaging as well as assessments of subjective experience. We are releasing this unique dataset as a resource for neuroscientists to study the acute and persistent effects of PSIL and MTP on brain networks.
Psilocybin (PSIL) is a serotonin 2A (5-HT2A) agonist that has shown rapid and sometimes persistent benefits in clinical trials for conditions such as depression, end-of-life anxiety, obsessive–compulsive disorder, eating disorders, and alcohol use disorder. Previous human neuroimaging studies of psychedelics have reported acute decreases in functional connectivity within the default mode network and reduced fMRI signal power across cortex, but they have faced important limitations including inter-individual variability, head motion, autonomic changes, and potential vascular/neurovascular confounds that complicate interpretation of acute drug effects. Subramanian and colleagues aimed to address these limitations by applying a "precision imaging drug trial" (PIDT) approach, which builds on precision functional mapping (PFM) through dense repeated resting-state fMRI sampling, individualized network mapping, physiological monitoring, and advanced multi-echo acquisition and denoising. The study used a randomised cross-over design in healthy adults to compare acute and persistent brain effects of a single 25 mg oral dose of psilocybin versus an active control (40 mg methylphenidate, MTP), and included longitudinal follow-up and a replication protocol in a subset of participants. The dataset combines multi-echo resting and task fMRI, structural MRI, diffusion basis spectrum imaging, and detailed subjective and physiological measures, and is released as a resource to study individual differences and common network-level effects of psilocybin.
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Design and participants. The study used a randomised, double-blind cross-over PIDT design in seven healthy adults (mean age 34.1 years, SD 9.8; 3 females; 6 Caucasian) recruited between March 2021 and March 2023. Eligibility required age 18–45 and at least one prior lifetime psychedelic exposure more than six months before enrolment; exclusions included MRI contraindications, major medical or psychiatric conditions, current psychotropic medications, pregnancy, prior adverse psychedelic reactions, and first-degree family history of psychosis. Four participants later returned for an open-label replication PSIL dose 6–12 months after the initial protocol. Interventions, blinding and facilitation. Each participant completed two drug sessions one to two weeks apart, receiving either PSIL 25 mg or MTP 40 mg per session. MTP was chosen as an active control to approximate cardiovascular and arousal effects. Both participants and facilitators were blinded during the cross-over. Dosing sessions lasted 7–8 hours and involved preparatory and post-session integration meetings; two trained facilitators (a clinician and a trainee) attended each dosing day. Participants completed mindfulness, wore eye shades and headphones with a curated music sequence, and were moved to the MRI suite about 60 minutes after ingestion for imaging during peak drug concentration. Imaging acquisition. MRI was performed on a Siemens Prisma. Sessions included high-resolution structural scans (T1/T2 at 0.9 mm isotropic), multi-echo EPI resting state scans (two or more 15-minute runs, 513 frames each) and two task fMRI runs (auditory–visual matching, 410 seconds each). Multi-echo parameters comprised five echo times (approximately 14.2, 38.9, 63.7, 88.4, 113.1 ms) with TR 1761 ms and 72 axial slices. Diffusion acquisitions optimised for diffusion basis spectrum imaging (DBSI) included b = 1500 and 3000 with 102 directions each; diffusion scans during PSIL were omitted when needed for participant comfort or time constraints. FIRMM head-motion monitoring and eye tracking were used during scanning; a subset of sessions included pulse oximetry and respiratory belt recordings for physiological regression. Behavioural and physiological measures. Subjective measures included the MEQ30 (mystical experience), Mini-IPIP (Big Five personality), Challenging Effects Questionnaire, and Emotional Breakthrough Inventory, administered at baseline and post-drug time points. Physiological signals were recorded at 400 Hz and preprocessed with PhysIO; instantaneous pulse and respiratory rates were calculated and used to generate regressors for nuisance removal in fMRI analyses. Preprocessing and analysis pipeline. Resting fMRI preprocessing included NORDIC thermal noise removal, slice timing correction, affine motion correction and registration, de-banding, spin-echo fieldmap correction (FSL top-up), gain field correction, FreeSurfer segmentation for tissue regression, temporal filtering (0.009–0.08 Hz), and frame censoring at FD > 0.30 mm. Multi-echo echoes were combined after registration using a weighted summation approach. Processed data were sampled into a 385-region parcellation (324 cortical, 61 subcortical) for functional connectivity analyses. Key analyses reported for the dataset included parcel-level FC similarity matrices, infra-slow spectral power (0.009–0.06 Hz), and network modularity (Newman's Q). A linear mixed-effects modelling framework with random effects for participant and MRI session was used to test drug-condition effects on modularity and infra-slow power; similarity matrices were compared via Pearson correlation of vectorised FC matrices.
Participants and data availability. Seven participants completed the main cross-over protocol and consented to public data sharing; four participants completed a replication PSIL session 6–12 months later. All raw and processed imaging and behavioural data are publicly available on OpenNeuro in BIDS format, organised by session with accompanying session notes and behavioural files. Subjective effects and adverse events. Mystical experience scores (MEQ30) were significantly higher on PSIL than on MTP across the four MEQ domains (p < 0.05). Mean domain scores (out of 5) for PSIL versus MTP were: mystical 3.4 versus 0.61, positive mood 3.8 versus 1.2, transcendence 3.8 versus 0.33, and ineffability 3.7 versus 0.86. One participant (P3) reported higher MEQ30 subscale scores on MTP than PSIL during the cross-over, but on return for the replication PSIL session they reported higher mystical scores consistent with other participants. Side effects 4–6 hours after PSIL ingestion included headache in one participant (14%), nausea in two participants (28%), and anxiety in two participants (28%). No serious adverse events occurred and no participants required rescue medication. Participant blinding was generally preserved; only P3 reported an incorrect treatment guess. Imaging data quantity and motion. The PIDT strategy produced a comparatively large dataset per participant: across protocol and replication visits participants provided an average of 39.4 (SD 12.2) off-drug 15-minute resting-state scans. On average there were 4.7 (SD 2.0) usable 15-minute resting scans per participant on PSIL and 2.7 (SD 0.8) on MTP. Using a stringent cutoff for usable scans (average FD ≤ 0.2 mm), 86% (6/7) of participants had at least one usable 15-minute PSIL resting scan; participant P2 lacked usable PSIL resting data. The authors note improved data quality relative to earlier psychedelic fMRI datasets. Physiological measures. Baseline session means were a pulse rate of 72 bpm (95% CI 68–77) and a respiratory rate of 11 respirations per minute (95% CI 9–13). Drug sessions produced changes in physiological signals relative to baseline; the text reports that MTP was associated with an average 16.7 bpm increase in pulse rate, although the accompanying confidence interval is not clearly reported in the extracted text. Non-drug sessions showed no consistent changes. Connectomics and network metrics. Whole-brain FC similarity matrices revealed two principal sources of similarity: within-participant across sessions and within-condition (for example, PSIL-to-PSIL). The PSIL condition was consistently less like other conditions within-subjects, indicating a distinct acute network signature, while PSIL–PSIL comparisons showed similarity within and across participants suggesting shared effects of PSIL. Network modularity (a measure of network segregation) decreased substantially from baseline during PSIL (P = 1.8754 × 10^-9) but did not remain significantly altered in the weeks following PSIL (P = 0.68). MTP produced no significant change in modularity (P = 0.85). Intra-participant reliability. Among the four participants who returned for the replication PSIL dose, whole-brain network changes were similar between the initial and replication PSIL sessions: similarity to replication r = 0.78, similarity across participants r = 0.45, P < 0.001. One participant (P2) was excluded from some analyses because of excessive motion leading to unusable data.
Psilocybin (PSIL) is a serotonin receptor 2 A (5-HT2A) agonist that has shown positive, rapid benefits in clinical trials for numerous psychiatric indications, including depression, end-of-life anxiety, obsessive compulsive disorder, eating disorders, and alcohol use disorder. These trials have found immediate (hours to days) and persistent (weeks to months) benefit from a single dose, making PSIL a promising treatment with broad applications in psychiatry. The neurobiological mechanisms of PSIL's immediate and persistent effects remain an active and important area of investigation. Persistent effects include increases in positive mood and the personality domain of openness. The discussion on therapeutic mechanisms of psychedelic drugs has focused on the acute subjective psychological experience, including the profound mystical experience frequently reported by individuals undergoing psychedelic therapy. However, to understand how these drugs produce a persistent clinical response (i.e., post-acute drug effects), it is necessary to understand circuit adaptations underlying a drug's psychological effects. Functional magnetic resonance imaging (fMRI) has been used to explore the effects of psychedelic compounds on human brain circuits. Recent studies using MRI to probe acute effects of psychedelics have reported decreases in functional connectivity in the default mode networkand an overall decrease in fMRI signal power across the cortex. Psychedelic brain imaging continues to face challenges and limitations. Individual variability, head motion, autonomic arousal, and changes to vascular and/or neurovascular couplinghave been potential confounds in prior fMRI studies accessing acute psychedelic effects. To overcome these aforementioned limitations, we applied a series of neuroimaging advancements that we have termed "precision imaging drug trial" (PIDT). PIDT builds on the principals of precision functional mapping -using dense repeated sampling and individualized network mapping and analysis -to account for inter-individual variability and overcome many limitations of conventional resting state fMRI. Precision functional mapping has revealed new details of cortical and subcortical brain network organization obscured by conventional group-average techniquesand large within-participant changes in network organization following an intervention. We recruited healthy adults to participate in a cross-over PIDT trial comparing brain effects of PSIL (25 mg dose) or active placebo (methylphenidate, MTP, 40 mg dose) (Fig.). Seven individuals underwent dense repeated sampling with resting state and task-based fMRI before, after, and during drug exposure. To assess variability of PSIL's effects within and across individuals, four participants received a second open-label dose of PSIL after six months ("replication protocol"). Our PIDT approach implemented Framewise Integrated Real-time MRI Monitoring (FIRMM), multi-echo EPI imaging, Nordic thermal de-noising, monitoring and regression of physiological signals (pulse-ox, respiratory belt) to provide state-of-the-art data quality and spatial resolution of longitudinal connectomics measurements. Here, we present a dataset suited to explore a range of questions about the individual differences and shared effects of PSIL on brain networks. This dataset substantially expands the existing body of available psychedelics fMRI data. As McCullough et al. point out in their review, over 50% of the published literature on psychedelics effects on rsfMRI are based on two data sets. This may be due to the barriers involved in researching psychedelic compounds. To aid other scientists interested in creating similar datasets, we summarize study challenges and potential solutions to such research in Supplementary Table. Using this dataset, we recently reported that: (1) Acutely, PSIL produced context-dependent desynchronization of brain activity, and individual differences were strongly linked to the subjective psychedelic experience. (2) Persistent decreases in hippocampus-default mode network connections were observed up to three weeks after, suggesting a neuroanatomical and mechanistic correlate of PSIL's long-term effects.
Study design and rationale. We designed a randomized controlled cross-over study (Fig.), using a PIDT design to evaluate individual-level brain connectivity pre-, post-and during PSIL or MTP exposure. Healthy adults were selected as the study population to reduce potential confounds from psychiatric diagnoses and/or medications. To reduce negative effects of drug exposure on participant experience, anticipatory anxiety, and imaging quality, participants were required to have had at least one previous lifetime psychedelic exposure and Fig.Graphical abstract: PICOT (Participants, Intervention, Control, Outcomes, Timing). This study recruited healthy adults with previous psychedelic exposure. Participants were enrolled in a cross-over study design using a precision functional mapping (PFM) approach. Key inclusion and exclusion criteria are listed, see methods section for complete list of criteria. Outcomes included subjective experiences, cognitive flexibility, and extensive MRI (including structural, task-based, resting state, and diffusion). MRI sequences were performed before the first drug, during the first and second drug, between the first and second drug, and after the second drug. A subset of participants also wore pulse oximeter and respiratory belt during MRIs for physiological assessments. Four out of seven participants completed the replication protocol. no psychedelic exposure in the six months before study participation. Usona Institute, a United States non-profit medical research organization with FDA authorization to produce medical-grade PSIL, provided PSIL 25 mg pills. Participants underwent two separate imaging sessions during active drug exposure: one with PSIL (25 mg) and one with MTP (40 mg). Drug sessions were spaced one to two weeks apart. MTP was selected as the active control condition to match the cardiovascular effects and physiological arousal (i.e., controlling for dopaminergic effects on blood pressure and heart rate) associated with PSIL. Six months after completing the initial study, participants were invited to participate in a replication protocol including a baseline fMRI and another dose of PSIL (25 mg) with brain imaging. Two clinical research staff who completed the Usona Institute facilitator training program facilitated the drug sessions. The role of the study facilitators was to build a rapport with the participant throughout the study, prepare them for their drug dosing days, and monitor participant safety during dosing day visits. The facilitation pair consisted of a trained clinician (J.S.S. and S.S.) and a trainee (D.P. and C.H.). At least three non-drug imaging sessions were completed before, between and after drug sessions (e.g., at least nine non-drug imaging sessions total). Dosing day imaging sessions started 60 minutes after drug administration and lasted ~120 minutes, spanning the period of peak blood concentration. The number of non-drug sessions was dependent on availability of the participant, scanner, and scanner support staff. Scans occurred at the same time of day for each participant. Inclusion/exclusion criteria. Healthy adults between the ages of 18 and 45 years with previous psychedelic exposure (>6 months prior to enrollment) were recruited via campus-wide advertisement and colleague referral. Participants were enrolled from March 2021 to March 2023. Exclusion criteria included: contraindications to MRI scanning (e.g., bone hardware, implantable devices, IUD); contraindications to PSIL exposure (e.g., cardiovascular disease, hypertension, renal disease, neurological condition, or pregnancy); diagnosis of psychiatric condition (including substance use disorders); current use of any psychotropic medication (e.g., TCAs, SSRIs, SNRIs, MAOIs, antipsychotics, lithium, valproate, tramadol); previous adverse reactions to psychedelics; immediate family history of any psychotic disorder (e.g., schizophrenia spectrum or psychotic mood disorders).
After providing informed consent, participants underwent screening tests, including an electrocardiogram, urine drug screen, basic metabolic panel, complete blood count and a urine pregnancy test. A study physician acquired a medical history, performed a physical exam, and reviewed labs to ensure that participants did not have exclusionary health conditions. Once medically cleared, participants were scheduled for imaging sessions and drug dosing days to ensure appropriate timing of pre-, post-, and dosing day scans (see 'Imaging visits' and 'Medication visits' below). Supplementary Tableillustrates the study's schedule of activities.
Assessments were conducted before, during, and after treatment sessions. Subjective data and objective measures of the medication experiences were collected, as well as a personality survey and safety parameters. Assessments obtained are described below: International personality item pool-five-factor model (Mini-IPIP). The Mini-IPIP is a 20-question staff-administered survey to determine the Big Five factors of an individual's personality: extraversion, agreeableness, conscientiousness, neuroticism, and openness to experience. The Mini-IPIP was administered at the following time points: baseline, post-drug one, and post-drug two.
The MEQ30 is a 30-item self-reported questionnaire that measures mystical experiences. It measures four factors: a) mystical (freedom from boundaries of one's personal self and a feeling of unity to what is greater than one's self), b) positive mood (sense of awesomeness or awe), c) transcendence of time and space (being outside of real of time), d) ineffability (sense that experience cannot be described well in words). The MEQ30 was administered at the following time points: baseline, post-drug one, post-drug two. We administered the MEQ30 on the same day of drug administration. Challenging effects questionnaire. This self-report questionnaire evaluates challenging experience with psychedelics (panic or fear, grief, isolation, feeling as though one is dying, feeling insane, physiological distress, and paranoia). It was be administered as part of the pre-screening phone assessment to determine eligibility, and was repeated 24 hours post-drug one and post-drug two. Emotional breakthrough inventory. This is a 6-item survey that was used to assess if the psychedelic experience produced an emotional breakthrough.
For each participant, all imaging visits were scheduled at the same approximate time of day (e.g., morning, afternoon, evening) to minimize time-of-day effects. The goal was to have visits occurring on days 1-2, 3-4, 5-7, and ~14 after each drug. For replication protocol visits, the goal was to have at least one MRI visit before and one visit after PSIL dose. MRI Acquisition. MRI scanning was conducted on a Siemens Prisma MRI scanner (Siemens, Erlangen, Germany). Imaging session timelines are illustrated in Fig.. Imaging sessions included a combination of structural MRI (T1-and T2-weighted images), two or more resting state fMRI scans (513 frames, 15 minutes each), and two sessions of task fMRI scans (233 frames, 6 minutes and 50 seconds each). Structural scans were obtained at 0.9 mm isotropic resolution. Resting state and task scans used an echoplanar imaging sequence with multi-echo (five TEs: 14.20 ms, 38.93 ms, 63.66 ms, 88.39 ms, 113.12 ms), TR 1761 ms, flip angle = 68 degrees, and in-plane acceleration (IPAT/grappa) = 2. This sequence acquired 72 axial slices (144 mm coverage). For resting state and task fMRI, three frames at the end were utilized to estimate electronic noise. During all imaging sessions, FIRMM was used to provide feedback on head motion during scanningand eye tracking was used to ensure that participants remained awake. Participants were provided with feedback about head motion between scans. Resting state fMRI. During resting state fMRI scans, participants were instructed to visually fixate on a white crosshair presented on a grey background. We aimed to acquire a minimum of two 15-minute resting state fMRI scans per visit. Given that optimal data cleaning has been shown to remove up to 25% of the data, 30 minutes of multi-echo resting state fMRI was necessary to measure cortico-subcortical networks. Task based fMRI. During some MRI visits, participants completed two event-related fMRI task scans. This was a suprathreshold auditory-visual matching task in which participants were presented with a naturalistic visual image (duration 500 ms) and coincident spoken English phrase. They were asked to respond with a button press to indicate if the image and phrase were 'congruent' (for example, an image of a beach, and the spoken word "beach") or 'incongruent' . Both accuracy and response time of button presses were recorded. Each trial was followed by a jittered inter-stimulus interval optimized for event-related designs. Task fMRI scans employed the same sequence used in resting fMRI, included 48 trials (24 congruent, 24 incongruent), and lasted 410 seconds each.
Given that increasing evidence suggests that psychedelics work as potent anti-inflammatory agents, coupled with the key role inflammation plays in psychiatric illnesses, we acquired diffusion MRI using sequences optimized for diffusion basis spectrum imaging (DBSI). This included acquisitions with b-values of 1500 and 3000, each with 102 directions (TR=3500ms, TE = 83 ms) -identical to sequences being used in ABCD. DBSI models inflammation-associated cellularity (DBSI-restriction fraction, RF) and vasogenic edema (DBSI-hindered fraction, HF) while accounting for partial volume effects resulting from cerebrospinal fluid contamination and crossing fibers. Diffusion scans on PSIL were omitted if there were time constraints or to mitigate a participant's comfort level. Physiological assessments. A subset of participants wore a Siemens built-in respiratory belt and a pulse oximeter during all MRI sessions (Table). Prior to MRI scanning, a belt was placed around the individual's thorax, with the sensor just below the ribcage. A pulse oximeter was placed on the non-dominant index finger. All data from respiratory belt and pulse oximeter were preprocessed using PhysIOto extract pulse-and respiration-based metrics, fMRI-aligned time courses, as well as physiological regressors for nuisance regression of fMRI data. Preparation and integration sessions. In addition to undergoing MRI sessions, preparation and integration sessions were held in a dedicated research treatment room where the study drug was also administered. Preparatory sessions were held one or two days before drug administration. Integration sessions were held one day after drug administration. The purpose of preparatory sessions was to build a therapeutic alliance between facilitators and participants. The participant's personal history, developmental stage, current life situation, and intentions for and expectations of drug sessions were reviewed. Integration sessions involved discussing experiences that emerged throughout the dosing session and the day after drug exposure. Preparation and integration sessions occurred per Usona clinical study guidelines. Drug dosing visits. Drug administration. Participants received either 25 mg of PSIL or 40 mg of MTP. Both facilitators and subjects were blinded. Medications were taken with water and lemon ginger tea. Mindfulness occurred for 10 minutes, and then participants were invited to lie on the sofa with eye shades as well as headphones. A curated psychedelic music sequence played through the headphones to reduce external stimulation. One hour after drug administration, participants were transported to the MRI suite wearing headphones and eye shades. Following the MRI, participants were transported back to the dedicated testing room and encouraged to direct their attention internally until subjective drug effects were completely resolved. Study facilitators then completed a modified post-session integration checklist with participants. Dosing sessions for both drugs were 7-8 hours in length. Patient safety and monitoring. As both PSIL and MTP impact cardiac and vascular functioning, heart rate and blood pressure were measured at regular intervals during dosing days (e.g., 30, 60, 90, 120, 180, 240, 300, 360, 420, and 480 minutes after drug ingestion). At these intervals, we queried participants about adverse effects, including time of onset, time of resolution, event description, and whether intervention was required. Rescue medications (risperidone for agitation, lorazepam for anxiety, and niacin for chest pain) were available as needed. The Columbia Suicide Severity Rating Scale (C-SSRS) was used to assess for suicidal ideation and behavior during drug exposure. Participants had access to a physician who was physically present throughout dosing day. Treatment guess. After each medication dosing, participants were asked to guess whether they received PSIL or MTP. rsfMRI processing and surface projection. Preprocessing of fMRI data included: (1) removal of thermal noise using NORDIC (a local PCA approach in which temporal components of an fMRI signal that are indistinguishable from Gaussian noise are eliminated); (2) sync interpolation to correct asynchronous slice acquisition; (3) affine spatial registration of all volumes within a run; (4) exclusion of odd/even slice intensity differences from interleaved acquisition (debanding); (5) compute affine spatial registration across fMRI runs; (6) compute an run volume mean (of all low-noise volumes); (7) field distortion correction on the basis of a spin echo field maps using FSL top-up; and (8) gain field correction based on run volume mean using FSL fast(computed on the run volume mean).
Resampling in MNI152 2 mm 3 atlas space was accomplished for all echoes in one step combining (i) motion correction; (ii) distortion correction; (iii) gain field correction; (iv) linear registration of average volumes across visits; and (v) non-linear MNI152 atlas registration via the FSL FNIRT. The multi-echo data in MNI152 space then were combined using the weighted summation approach (as described in Posse et al. equations 6 and 7). After cross-modal registration, the data underwent several pre-processing steps. These included: FreeSurfer segmentation for tissue-based regression, elimination of signals with false variance, temporal filtering to include 0.009-0.08 Hz bands, and frame censoring. False signals included: six parameters obtained by rigid body correction of head motion, extra-axial noise, white matter, and ventricles. Frame censoring was performed on all resting state fMRI data at FD > 0.30 mm. After preprocessing, BOLD data was analyzed using each participant's cortical surface and nuclei. Voxels with high coefficients of variation were excluded from volume to surface mapping. Resting data was then sampled into a set of about 385 brain regions using a previously validated parcellation of cortical (324) and subcortical (61) brain areas. These regions can be used for functional connectivity analysis.
The primary goal of our study was to test significant differences between baseline and PSIL scans using a within-participant design, followed by testing if differences replicate across participants. For the present data resource, we conducted descriptive analytics on the participant population using behavioral assessments and physiological data. We also assessed imaging quality via assessing whole brain network similarity matrices and brain modularity. Physiological measurements were recorded at 400 Hz with clocked timestamps and extracted using PhysIO Toolboxas raw plethysmography signals. All signals were visually inspected and entire sessions were rejected if significant clipping occurred or if signals were noisy, without regular oscillations expected in pulse or respiratory plethysmography. We calculated instantaneous pulse rate (PR) and respiratory rate (RR) by labeling the peaks and troughs of the wave using Matlab's findpeaks function, and we then calculated pulse rate or respiratory rate between each peak. This custom rate calculation agreed with PhysIO toolbox for respiratory rate but offered higher temporal resolution with respect to pulse rate. Physiological regressors for fMRI analyses were created using the automated PhysIO Toolbox. A mixed linear effects model was used to determine the relative effects of MTP and PSIL on the session means of physiological parameters. For similarity matrix correlation calculations were performed at the parcel level. The effects of condition (baseline, PSIL, between, MTP, after), and participant were directly examined by calculating the similarity between each functional network matrix (i.e., Pearson correlation between the linearized upper triangles of the parcellated FC matrix between a pair of 15 minute fMRI scans), creating a second-order "similarity" matrix. Spectral power in the infra-slow band (0.009 to 0.06 Hz) was evaluated in each parcel as the cosine Fourier transform of the BOLD signal autocovariance function computed in a manner that allows for motion censoring. Spectral power was averaged over cortical parcels to generate a single value for each session. Modularity (Newman's Q) was calculated using the equation: where the network (including nodes and binary undirected links) is fully subdivided into a set of nonoverlapping modules M, and e uv is the proportion of all links that connect nodes in module µ with nodes in module ν. Matlab code to calculate modularity and other graph measures (below) was taken from the Brain Connectivity Toolbox, publicly available at sites google.com/site/bctnet/. A linear mixed effects model with random effects for participant and MRI session was used to test the effect of drug condition (PSIL, MTP, baseline, and post-PSIL) on modularity and BOLD infraslow power. Let y ij be the rs-fMRI metric (e.g. FC change score at a given vertex) for the j-th observation (15-minute fMRI scan) within the i-th participant. The linear mixed-effects model can be written as: • β 0 is the intercept term. • β drug , β FD , β task and β task*drug are the coefficients for the fixed effects predictors. • drug ij , FD ij , and task ij are the values of the fixed effects predictors for the j-th observation within the i-th group. • u 0i represents the random intercept for the i-th participant, accounting for individual-specific variability. • v 0j represents the random intercept for the j-th observation within the i-th participant, capturing scan-specific variability. • ε ij is the error term representing unobserved random variation.
Repository information. All imaging data (raw, minimally preprocessed, and fully processed) for participants (P1-P7) and replication sessions (P1R, R3R, P4R, P5R) are available on OpenNeuro (OpenNeuro Dataset ds006072,). All participants consented to have their data shared on a publically available archive. Images are in NifTI format, defaced, and in BIDS structure. Each participant has a folder containing subfolders with each scanning session. Within each session folder, "anat, " "dwi, " "fmap, " and "func" folders are present. Scanning dates, MRI sequences, and scan notes and complications are presented in "PPFM_session_notes.xslx" file in OpenNeuro. Scanning notes include: time frames in which participants may have fallen asleep, high degrees of head motion, FIRRM complications, scanner malfunction, and respiratory belt malfunction. Behavioral assessments such as mystical experiences and personality factors are provided in the folder "Behavioral Assessments". We briefly summarize demographic, behavioral, movement, and physiological data below. Participant demographics and characteristics. Seven adults consented and completed the study (mean age of 34.1 years, SD = 9.8). Three individuals were female, and six were Caucasian. Additional baseline characteristics of the study population are included in Table. See Supplementary Fig.for participant disposition. Subjective experiences and adverse events. Overall, self-reports of mystical experiences on PSIL vs. MTP (active placebo) were significantly higher (p < 0.05) across all four mystical factors. Average mystical, positive mood, transcendence, and ineffability domain scores (out of 5 points) were: 3.4 vs. 0.61, 3.8 vs. 1.2, 3.8 vs. 0.33, and 3.7 vs. 0.86 for PSIL vs. placebo, respectively (Fig.). One participant (P3) reported a higher MEQ30 score on MTP vs. PSIL. Specifically, this participant reported higher ineffability (4.2 vs. 0), transcendence (1.5 vs 1), and mystical experience (2.8 vs. 1.1) on MTP vs. PSIL. Positive mood was scored the same on both MTP and PSIL. When this participant came back for the replication protocol (i.e., received a second dose of PSIL), she obtained higher mystical experience scores: 4.1 on ineffability, score 5.0; transcendence, 2.1; mystical experience, 4.4, and positive mood, 4.1. P3 was the only participant who incorrectly guessed when they received PSIL and MTP on participant blinding questionnaires (e.g., stated "positive I received [active or placebo] drug"). Individuals stated that the multiple baseline scans prior to drug exposure improved the comfortability of being on a psychedelic in the MRI scanner. Four to six hours after PSIL ingestion, side effects reported included: 14% headache [n = 1], 28% nausea [n = 2], 28% anxiety [n = 2]. No serious adverse events occurred while participants were on PSIL or MTP and undergoing MRI. No participant required rescue medications.
Because psychedelics increase head movement, training participants beforehand to remain still and comfortable in the scanner was critical for the collection of behaviorally relevant brain-wide signals. Thus, participants underwent 4-9 non-drug MRI visits prior to their first drug imaging session and FIRMM was used to provide participants feedback about head motion at each session. Consequently, compared with prior psychedelics imaging datasets, participants were able to provide a greater quality (Fig.) and quantity (Fig.) of data while still achieving a mystical experience on PSIL (Fig.). Combining the protocol + replication visits, we obtained an average of 39.4 (SD = 12.2) "off drug" 15-minute resting state scans from 7 participants (Table). We obtained an average of 4.7 (SD 2.0) 15-minute resting state scans on PSIL per participant and 2.7 (SD = 0.8) 15-minute resting state scans on MTP. In this PIDT study, 86% (n = 6 out of 7) had at least one usable 15-minute resting scan on PSIL (i.e., framewise head motion was ≤ 0.2 mm). Only participant P2 did not. By comparison to prior PSIL dataset (Fig.), in Carhart-Harris et al. 2012 study of PSIL, 46% (n = 7 out of 15) had any usable resting state data (any scan with average framewise head motion less than or equal to 0.2 mm). In Carhart-Harris et al. 2016 study of LSD, 75% (n = 15 out of 20) had one resting state scan meeting framewise head motion requirements. Physiological data. Pulse and respiratory rates obtained during fMRI scans were analyzed within and across participants and conditions (Fig.). Within participant, baseline sessions (before drug 1) were used as the control condition to assess for both effect of drug and after-drug on pulse and respiratory rate. Changes were observed in drug conditions (MTP, PSIL) but no consistent changes were observed in off-drug conditions (between, after). Thus, for group-level analyses, non-drug sessions were combined and a mixed linear effects model was used to assess effects of MTP and PSIL on the physiological parameters. The average baseline pulse rate was 72 beats per minute (bpm, 95% CI, 68-77) and the respiratory rate was 11 respirations per minute (rpm, 95% CI, 9-13). A mixed linear effects model was used to determine the relative effects of MTP and PSIL on the session means of physiological parameters. On average, MTP was associated with a 16.7 bpm increase in pulse rate (95% Fig.Mystical Experiences Questionnaire (MEQ30) results. Data presented are mean and standard deviations of measurement in all seven participants. Participants were asked to look back on their drug experience on the same day of receiving PSIL or MTP and rate the degree to which they experienced criteria across five factors (transcendence, positive mood, ineffability, mystical) from a scale of 0 to 5. A score of 0 indicates did not experience at all, and a score of 5 is given to extremely experienced (more than any other time in their life). Asterisks: *p < 0.05, two-tailed t-test. Fig.Comparison of head motion to prior psychedelic fMRI datasets. Average head motion (framewise displacement, FD in millimeters) for each scan off (a) and on (b) psychedelic drug was compared between our dataset and prior psychedelic fMRI studies. In a/b, the dotted line at 0.2 mm represents a stringent cutoff for exclusion of a session. Sessions with average FD of 0.2 mm or lower are considered usable. Lower and upper quartiles of box-plots were calculated as follows: Q1-1.5 × IQR, Q3 + 1.5 × IQR, respectively. Asterisks indicate significant (* p < 0.05, **p < 0.005, unpaired t-test, two tailed) difference in head motion compared to two other highly cited datasets. (c) The totality of resting state data (usable and unusable) on psychedelic in minutes.
Similarity matrix and modularity. To explore macro trends in the data, we visualized whole-brain connectome similarity within and across participants (Fig.). The 5 × 5 red boxes observed along the diagonal demonstrate the overall similarly within-participant across sessions (as indicated by 'Within Participant' . And the 3 × 5 red rectangles on the top right and lower left corners represent within participant similarity when participants returned for replication protocol 6-12 months later. The PSIL condition stands out as substantially less like other conditions (including MTP) in every subject. Interestingly, there is PSIL-PSIL similarity within and across participants (suggested a shared effect of PSIL, as described in Siegel et al.). Network modularity, a measurement of brain-network segregation, was recently shown to significantly decrease in individuals with treatment-resistant depression following treatment with PSIL. In our dataset, network modularity decreased from baseline during PSIL (P = 1.8754*10 -9 ) but did not remain significantly changed in the weeks following PSIL (Fig.; P = 0.68). MTP also had no significant effect on modularity (P = 0.85). Intraparticipant reliability. To assess variability in effects of PSIL within-participant across doses, four participants underwent a second PSIL dose 6-12 months after their initial dose (including at least one MRI visit before and after dosing). Baseline, during PSIL, and post-PSIL rsfMRI, diffusion, structural, and task-based MRI were conducted. When individuals came back for the replication protocol, the second PSIL dose produced similar whole brain network changes (similarity to replication r = 0.78, similarity across participants r = 0.45, P < 0.001). Fig.Whole brain network similarity matrix and intra-subject data reliability. Each row and column represent brain networks (average FC matrix) from one participant in one study condition (baseline, Drug 1, between, Drug 2, after) and each edge represents similarity of functional networks between a pair of conditions. Networks from the replication protocol are shown at the end of the matrix. The diagonal represents the similarity between all scans within the same classification (e.g., all baseline scans for P1). Note: for MTP and PSIL sequences, fMRI comparisons are among resting state scans acquired during that same 'on drug' MRI sequence. To the right, a visualization of data structure demonstrates two sources of similarity -'within participant' and 'within class' (e.g. brain networks from two participants' PSIL condition). For example, Participant 1's whole brain functional networks without and on drug sessions are similar when compared to themselves vs. Participant 4 (see solid black squares in chart). When Participant 1 came back for replication, their whole brain functional networks on PSIL were highly correlated to their replication session on PSIL six months later (see dotted box in chart). Participant 2 was excluded, given a large degree of unusable data (framewise head displacement > 0.2 mm).
Create a free account to open full-text PDFs.
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)
Raison, C. L., Sanacora, G., Woolley, J. D. et al. · JAMA (2023)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Wilcox, C. E. · Journal of Psychoactive Drugs (2014)
Renelli, M., Fletcher, J., Tupper, K. W. et al. · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity (2018)
Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H. et al. · Frontiers in Pharmacology (2018)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)
Wall, M. B., Harding, R., Zafar, R. et al. · Molecular Psychiatry (2023)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Nicol, G. E. · Nature (2024)
Kargbo, R. B., Sherwood, A. R., Walker, A. et al. · ACS Omega (2020)
Holze, F., Becker, A. M., Kolaczynska, K. E. et al. · Clinical Pharmacology and Therapeutics (2022)
Brown, R. T., Nicholas, C. R., Cozzi, N. V. et al. · Clinical Pharmacokinetics (2017)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Flanagan, T. W., Nichols, C. D. · International Review of Psychiatry (2018)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Daws, R. E., Timmermann, C., Giribaldi, B. et al. · Nature Medicine (2022)